1. Introduction {#sec1}
===============

It is well known that oxidized low-density lipoprotein (LDL; ox-LDL) contributes to the pathogenesis of atherosclerosis. ox-LDL is recognized by macrophage scavenger receptors and then taken up through receptor-mediated endocytosis, ultimately leading to the formation of lipid-laden foam cells. This process is a critical event in atherosclerosis \[[@B1]\]. In addition to its role in lipid loading on macrophages, ox-LDL also has other biological functions, such as causing endothelial dysfunction and inducing smooth muscle cell proliferation, that contribute to the pathogenesis of atherosclerosis \[[@B2]\]. Accumulating evidence suggests that atherosclerosis is also a chronic inflammatory disease \[[@B3], [@B4]\]. However, the extent of involvement of ox-LDL in vascular inflammation is less understood.

Although the precise mechanism of LDL oxidation *in vivo* is not yet fully established, ox-LDL generated by exposure of LDL to Cu~2~SO~4~*in vitro* has been widely used in related studies. Only a few studies have used ox-LDL from natural sources. This could be due to the level of ox-LDL in natural sources being low and difficult to obtain, while copper- (Cu-) ox-LDL is relatively easy to prepare and is able to induce foam cell formation. In a previous study, we reported that electronegative LDL (LDL(-)) from the plasma of ST-elevated myocardial infarction (STEMI) patients induced production of interleukin- (IL-) 1*β* via the lectin-type oxidized LDL receptor- (LOX-) 1 in macrophages \[[@B5]\]. IL-1*β* is a central mediator of inflammation that was implicated in the development of atherosclerosis and acute myocardial infarction \[[@B6], [@B7]\]. Moreover, LDL(-), isolated from healthy normolipemic subjects, has been shown to induce production of GRO*β*, GRO*γ*, IL-6, IL-8, and MCP1 in human monocytes and lymphocytes \[[@B8]--[@B10]\]; induce IL-1*β* release in human monocytes and macrophages \[[@B11]\]; and induce production of MMP-9 and TIMP-1 in human monocytes \[[@B12]\]. Moreover, circulating ox-LDL was also associated with the plasma levels of tumor necrosis factor-*α* (TNF-*α*) and C-reactive protein (CRP) \[[@B13]\]. Those results suggested that LDL(-) has inflammatory properties. Naturally occurring LDL(-) was found to be elevated in the plasma of patients with hypercholesterolemia, type II diabetes, and STEMI \[[@B14]--[@B17]\], and all of those patients were associated with chronic inflammation \[[@B18]--[@B20]\]. Thus, LDL(-) may contribute to inflammation in these patients. In addition, our previous study showed that STEMI LDL(-) is more potent than Cu-ox-LDL in inducing IL-1*β* production by macrophages \[[@B21]\]. Those results suggested that the characteristics of LDL(-) and Cu-ox-LDL differed in terms of inducing inflammation.

Only a few papers have reported that plasma LDL(-) can be induced by an atherogenic diet \[[@B22], [@B23]\]; moreover, it is not clear if diet-induced LDL(-) is able to induce an inflammatory response in macrophages. Feeding cholesterol to rabbits is a widely used model for experimental atherosclerosis studies \[[@B24], [@B25]\]. We reported that an atherogenic diet induced inflammation in aortic atherosclerotic plaque and elevation of plasma ox-LDL, detected using an ox-LDL enzyme-linked immunosorbent assay (ELISA) kit, in rabbits \[[@B26]\]. In the present study, we isolated native LDL (nLDL) and LDL(-) from the plasma of rabbits fed an atherogenic diet. LDL(-) and nLDL were directly used or exposed to Cu~2~SO~4~*in vitro* for 24 h to produce extensively oxidized Cu-ox-nLDL and Cu-ox-LDL(-). Then, the effects of nLDL, LDL(-), Cu-ox-nLDL, and Cu-ox-LDL(-) on the production of the proinflammatory cytokines, IL-1*β*, IL-6, and tumor necrosis factor- (TNF-) *α*, and activation of nuclear factor- (NF-) *κ*B and mitogen-activated protein kinases (MAPKs) in macrophages were investigated.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

RPMI 1640, penicillin/streptomycin, fetal bovine serum (FBS), and L-glutamine were obtained from Gibco BRL/Life Technologies (Rockville, MD, USA). Dimethyl sulfoxide (DMSO), phorbol 12-myristate 13-acetate (PMA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO, USA). The Beckman Paragon System was from Beckman (Palo Alto, CA, USA). Human IL-1*β*, IL-6, and TNF-*α* ELISA kits were obtained from R&D Systems (Minneapolis, MN, USA). The Beckman Paragon System was from Beckman (Palo Alto, CA). A mouse monoclonal antibody against human *β*-actin was obtained from Chemicon (Temecula, CA, USA). Antibodies against ERK1/2, inhibitor of NF-*κ*B (I*κ*B), c-Jun N-terminal kinase (JNK), p38, and p65 were purchased Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against phosphorylated- (phospho-) I*κ*B were obtained from Abcam (Cambridge, UK). Antibodies against phospho-JNK, phospho-p65, phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/204), and phospho-p38 were obtained from Cell Signaling Technology (Danvers, MA, USA). U0126 (a MEK inhibitor), SB203580 (a p38 MAPK inhibitor), SP600125 (a c-Jun N-terminal kinase inhibitor), and LY294002 (a phosphoinositide 3-kinases inhibitor) were purchased from Calbiochem (San Diego, CA). A polyclonal lectin-type oxidized LDL receptor- (LOX-) 1 antibody was obtained from Biorbyt (San Francisco, CA, USA). A TRIzol reagent was purchased from Invitrogen (Carlsbad, CA, USA).

2.2. Animal Feeding and LDL Preparations {#sec2.2}
----------------------------------------

Sixteen-week-old male New Zealand White rabbits (\~2 kg) were allowed an acclimation period of 2 weeks and then were fed an atherogenic diet (chow supplemented with 5% lard and 0.25% cholesterol) for 2 months, after which blood was drawn from an ear vein and collected in tubes containing EDTA. Plasma was obtained by centrifugation of the pooled blood at 1400 g and 4°C for 10 min. LDL (*d* = 1.019--1.063 g/ml) was isolated by sequential ultracentrifugation from the plasma as described previously \[[@B21]\]. Isolated LDL was then resolved into nLDL and LDL(-) by anion-exchange chromatography on a fast protein liquid chromatographic system (AKTA Explorer; GE, Uppsala, Sweden) as described previously \[[@B5], [@B21]\], and levels of electronegativity were ascertained through agarose gel electrophoresis using the Beckman Paragon System and were performed according to the manufacturer\'s instructions \[[@B27]\]. All lipoprotein isolations were carried out within 5 days after the blood was obtained. Cu-ox-LDL was prepared by incubating nLDL with 10 *μ*M CuSO~4~ for 24 h; the reaction was stopped by the addition of EDTA and then dialyzed against 2000 volumes of PBS overnight \[[@B27]\]. Precautions were taken to prevent all LDL preparations from endotoxin contamination and further oxidation \[[@B5], [@B21]\]. The degree of lipid peroxidation in LDL was determined by measuring thiobarbituric acid-reactive substances (TBARS) using a commercial kit (Cayman, Ann Arbor, MI, USA) according to the manufacturer\'s protocol. Malondialdehyde (MDA) was used as a standard. Protein concentrations were estimated by the Bradford method (DC Protein Assay Reagent, Bio-Rad, Hercules, CA, USA).

2.3. Cell Culture and Lipoprotein Treatment {#sec2.3}
-------------------------------------------

The THP-1, a human monocytic leukemia cell line, was obtained from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI 1640 containing 10% FBS as described previously \[[@B5], [@B21]\]. In these experiments, 2 × 10^5^ cells/well were seeded on 24-well plates and induced differentiation into macrophages by being cultured for 3 days with a medium containing 160 nM PMA. Cells were then cultured in a serum-free RPMI culture medium and treated with 10\~40 *μ*g/ml nLDL, LDL(-), or Cu-ox-LDL for 24 h or as indicated. Control cells were treated with phosphate-buffered saline (PBS) in all experiments or as indicated. The culture medium was collected, and levels of cytokines in the medium were determined.

2.4. Quantification of IL-1*β*, IL-6, and TNF-*α* in the Culture Medium {#sec2.4}
-----------------------------------------------------------------------

Levels of IL-1*β*, IL-6, and TNF-*α* in the culture medium were analyzed by ELISA kits (R&D Systems). All assays were performed according to the manufacturer\'s instructions.

2.5. Western Blot Analysis {#sec2.5}
--------------------------

Cells were washed with cold PBS and then lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl at pH 7.8, 5 mM EDTA at pH 8.0, 0.5% NP-40, 0.5% Triton X-100, 0.1% sodium dodecyl sulfate (SDS), 1 mM NaF, 1 mM PMSF, 1 mM Na~3~VO~4~, and 1x protease inhibitor cocktail). Protein concentrations were determined by the Bradford method. Proteins (20 *μ*g/well) were loaded and separated on SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a polyvinylidene difluoride membrane. Levels of ERK1/2, I*κ*B, JNK, p38, p65, phospho-ERK1/2, phospho-I*κ*B, phospho-JNK, phospho-p38, phospho-p65, LOX-1, and *β*-actin were detected using specific antibodies. Bound antibodies were detected using a luminescence imaging system (Fujifilm LAS 4000, Tokyo, Japan). Protein levels on Western blots were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

2.6. Statistical Analysis {#sec2.6}
-------------------------

Results are shown as the mean ± standard deviation (SD) or standard error (SE). Differences between means were evaluated using Student\'s *t*-test or by one-way ANOVA followed by Tukey\'s multiple comparison test and were considered significant at *p* \< 0.05.

3. Results {#sec3}
==========

3.1. LDL(-) Induced Production of IL-1*β*, IL-6, and TNF-*α* by Macrophages {#sec3.1}
---------------------------------------------------------------------------

Rabbit plasma total and LDL cholesterol were 56.0 ± 11.0 and 19.5 ± 4.2 mg/dl, respectively, and LDL(-) were not detected in the anion-exchange chromatography in rabbits feeding with the control chow diet. Plasma total cholesterol (C) and LDL-C were 172.1 ± 46.2 and 98.9 ± 23.8 mg/dl, respectively, at 4 weeks and were 342.7 ± 44.5 and 183.1 ± 35.6 mg/dl, respectively, at 12 weeks after feeding with the atherogenic diet. LDL(-) was isolated from plasma of 2 to 3 rabbits each time, and LDL(-) accounted for about 17.2 ± 5.5% of the LDL fraction (ranging from 10 to 27%) ([Figure 1(a)](#fig1){ref-type="fig"}). Agarose gel electrophoresis confirmed the electronegativity of rabbit LDL(-) ([Figure 1(b)](#fig1){ref-type="fig"}). To examine the effects of nLDL and LDL(-) on inflammatory cytokine production by macrophages, THP-1 macrophages were treated with 20 *μ*g/ml nLDL or LDL(-) for 24 h, and then levels of IL-1*β*, IL-6, and TNF-*α* proteins in culture media were determined. There were negligible levels of IL-1*β*, IL-6, and TNF-*α* in the control cells. Treatment with LDL(-) led to 3.7-, 2.7-, and 7.2-fold increases in IL-1*β*, IL-6, and TNF-*α* production, respectively, compared to treatment with nLDL (Figures [2(a)](#fig2){ref-type="fig"}--[2(c)](#fig2){ref-type="fig"}). Treating THP-1 macrophages with LDL(-) (10, 20, and 40 *μ*g/ml) for 24 h induced dose-dependent increases in IL-1*β*, IL-6, and TNF-*α* (Figures [2(d)](#fig2){ref-type="fig"}--[2(f)](#fig2){ref-type="fig"}). In addition, treatment with LDL(-) (20 *μ*g/ml) for 6\~24 h induced time-dependent increases in IL-1*β*, IL-6, and TNF-*α*, and all had achieved a significant increase after 6 h (Figures [2(g)](#fig2){ref-type="fig"}--[2(i)](#fig2){ref-type="fig"}).

3.2. LDL(-) Induced Activation of NF-*κ*B and Expressions of NF-*κ*B Downstream Genes {#sec3.2}
-------------------------------------------------------------------------------------

In a previous study, we demonstrated that STEMI LDL(-) induced activation of NF-*κ*B in macrophages \[[@B5]\]. To investigate whether rabbit LDL(-) is able to induce the activation of NF-*κ*B and expressions of IL-1*β*, IL-6, and TNF-*α* messenger RNAs (mRNAs), macrophages were treated with 20 *μ*g/ml nLDL or LDL(-). Then, protein levels of total and phospho-I*κ*B were determined by Western blotting, and levels of IL-1*β*, IL-6, TNF-*α*, CD86, and IL-10 mRNAs were determined by a quantitative reverse-transcription polymerase chain reaction (RT-qPCR). Figures [3(a)](#fig3){ref-type="fig"}--[3(c)](#fig3){ref-type="fig"} shows that levels of phospho-I*κ*B and phospho-p65 were slightly induced by nLDL but were greatly induced by LDL(-) at 2 h. In addition, LDL(-) induced 2.4-, 2.2-, 3.4-, and 2.2-fold increases in IL-1*β*, IL-6, TNF-*α*, and CD86 mRNA levels, respectively, compared to nLDL-treated cells ([Figure 3(d)](#fig3){ref-type="fig"}). CD86 is a marker for M1 (classically activated) macrophages; the result suggests that LDL(-) induced THP-1 polarized toward a proinflammatory type. However, the levels of the anti-inflammatory cytokine IL-10 mRNA were about the same in the nLDL- and LDL(-)-treated cells. We then tested if LDL(-)-induced proinflammatory cytokines could be inhibited by an NF-*κ*B inhibitor, BAY 11-7082. Results showed that BAY 11-7082 significantly inhibited LDL(-)-induced IL-1*β*, IL-6, and TNF-*α* (Figures [3(e)](#fig3){ref-type="fig"}--[3(g)](#fig3){ref-type="fig"}).

3.3. LDL(-)-Induced IL-1*β*, IL-6, and TNF-*α* Production via a LOX-1-Dependent Pathway {#sec3.3}
---------------------------------------------------------------------------------------

LOX-1 and CD36 are considered major receptors for mildly oxidized LDL \[[@B28]\]. The roles of LOX-1 and CD36 in LDL(-)-induced IL-1*β*, IL-6, and TNF-*α* expressions were investigated using LOX-1- and CD36-knockdown cells, with LacZ-knockdown cells used as a knockdown control. Knockdown cells were generated as described in previous studies \[[@B5], [@B21]\]. Figures [4(a)](#fig4){ref-type="fig"}--[4(c)](#fig4){ref-type="fig"} shows that levels of IL-1*β*, IL-6, and TNF-*α* were low in control LOX-1-, CD36-, and LacZ-knockdown cells. LDL(-) induced IL-1*β*, IL-6, and TNF-*α* to similar levels in LacZ- and CD36-knockdown cells; however, LDL(-)-induced IL-1*β*, IL-6, and TNF-*α* were significantly lower in LOX-1-knockdown cells. These results suggest that LDL(-) induced IL-1*β*, IL-6, and TNF-*α* through a LOX-1-dependent pathway in macrophages.

3.4. LDL(-) Is More Potent than Cu-ox-LDL in Inducing Production of IL-1*β*, IL-6, and TNF-*α* and Activation of NF-*κ*B and MAPKs in Macrophages {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------------

LOX-1 has been shown to have a higher reactivity with mildly ox-LDL, such as LDL(-), than with extensively oxidized LDL \[[@B29]\]. We then compared the proinflammatory effects of LDL(-) and extensively ox-LDL. To prepare extensively ox-LDL, nLDL and LDL(-) were incubated with copper for 24 h to, respectively, produce Cu-ox-nLDL and Cu-ox-LDL(-). The degrees of oxidation were estimated by measuring TBARS. Levels of TBARS with nLDL and LDL(-) were both \<1 nmol/mg protein, while levels of TBARS with Cu-ox-nLDL and Cu-ox-LDL(-) were 17.6 and 15.8 nmol/mg protein, respectively. Then, 20 *μ*g/ml nLDL, LDL(-), Cu-ox-nLDL, and Cu-ox-LDL(-) were incubated with THP-1 macrophages for 24 h. [Figure 5](#fig5){ref-type="fig"} shows that Cu-ox-nLDL induced higher levels of IL-6 than nLDL but not the levels of IL-1*β* and TNF-*α*. However, oxidation of LDL(-) resulted in decrease of its ability to induce IL-1*β*, IL-6, and TNF-*α*. Cu-ox-LDL(-) induced lower levels of IL-1*β*, IL-6, and TNF-*α* than did LDL(-). Further, LDL(-) induced significantly higher levels of IL-1*β*, IL-6, and TNF-*α* than did either nLDL or Cu-ox-nLDL ([Figure 5](#fig5){ref-type="fig"}). These results show that LDL(-) is more potent in inducing IL-1*β*, IL-6, and TNF-*α* than nLDL and extensively ox-LDL.

3.5. Effects of LDL(-) and Cu-ox-nLDL on Phosphorylation of I*κ*B, p38, ERK1/2, and JNK {#sec3.5}
---------------------------------------------------------------------------------------

Next, we compared the effects of LDL(-) and Cu-ox-nLDL (20 *μ*g/ml) on inducing levels of phosphorylated I*κ*B and MAPKs, including p38, ERK1/2, and JNK. [Figure 6](#fig6){ref-type="fig"} shows that the levels of phosphorylated I*κ*B, MAPK-p38, ERK1/2, and JNK were all greatly induced by LDL(-) but the levels were not induced by Cu-ox-nLDL. To examine the involvement of MAPKs in LDL(-) induction of IL-1*β*, IL-6, and TNF-*α* in THP-1 macrophages, cells were pretreated for 30 min with 10 mM of U0126, 50 mM of LY294002, 20 mM of SB203580, 0.5 mM of L-JNKi 1 trifluoroacetate, or DMSO (vehicle). Subsequently, 20 mg/ml of LDL(-) was added and incubated for 24 h. [Figure 7](#fig7){ref-type="fig"} shows that LDL(-)-induced IL-1*β*, IL-6, and TNF-*α* were all inhibited by U0126; in addition, LDL(-)-induced IL-6 and TNF-*α* were moderately inhibited by SB203580. These results suggest that LDL(-)-induced IL-1*β* occurs through an ERK1/2-dependent pathway and induction of IL-6 and TNF-*α* occurs through p38- and ERK1/2-dependent pathways.

4. Discussion {#sec4}
=============

In this study, we showed that an atherogenic diet induced generation of LDL(-), a type of circulating ox-LDL, in rabbits. We also demonstrated that LDL(-) is potent in inducing activation of NF-*κ*B and MAPK signaling pathways and production of IL-1*β*, IL-6, and TNF-*α* in THP-1 macrophages. IL-1*β* is a major proinflammatory cytokine in the pathogenesis of cardiovascular diseases. Knockout IL-1*β* in atherosclerosis-prone ApoE-deficient mice leads to attenuation of atherosclerosis development \[[@B30]\]. Moreover, blocking IL-1*β* with a monoclonal antibody, canakinumab, has resulted in a lower rate of recurrent cardiovascular events, cardiovascular complications, and cardiovascular mortality in patients with MI \[[@B31]\]. IL-6 is a pleiotropic cytokine that has been shown to contribute to atherosclerotic plaque development and plaque destabilization \[[@B32]\] and induction of the hepatic acute phase response protein such as C-reactive protein (CRP) \[[@B33]\], increasing the expression of ICAM-1 in endothelial cells \[[@B34]\]. TNF-*α* was originally identified as a circulating factor which can cause necrosis of tumors \[[@B35]\] and was also later found crucially involved in the pathogenesis and progression of atherosclerosis \[[@B36]\]. TNF-*α* induces expression of adhesion molecules, proinflammatory cytokines, and chemokine receptors in endothelial cells \[[@B37]\]. Therefore, induction of IL-1*β*, IL-6, and TNF-*α* by LDL(-) in macrophages has a link between LDL(-) and inflammation in hypercholesterolemia. In addition, higher levels of LDL(-) and inflammation were shown in hypercholesterolemic patients than in normolipidemic subjects \[[@B38]--[@B42]\]. Supplementary [](#supplementary-material-1){ref-type="supplementary-material"} shows that rabbit LDL(-) induced the granulocyte colony-stimulating factor (G-CSF) to a similar level as that induced by STEMI LDL(-) \[[@B21]\]. These properties revealed that LDL(-) is a highly atherogenic lipoprotein and imply a pathogenic role for LDL(-) in hypercholesterolemia.

Atherosclerosis is now considered a chronic inflammatory disorder \[[@B3], [@B4], [@B43]\]. Plasma levels of the proinflammatory cytokines IL-1*β*, IL-6, and TNF-*α* were higher in atherosclerotic patients than in normal subjects \[[@B44]\]. Moreover, an increased level of LDL(-) was associated with high cardiovascular risk \[[@B45], [@B46]\]. Our data showed that LDL(-) induced activation of NF-*κ*B and MAPKs and the subsequent production of proinflammatory cytokines in macrophages; hence, LDL(-)-activated macrophages may be associated with inflammation in atherosclerosis. Our preliminary studies showed that replacing the atherogenic diet with normal chow would decrease levels of both LDL and LDL(-) in rabbits and hamsters. Clinical studies demonstrated that statin therapy results in a progressive decrease in the proportion of LDL(-) and attenuates inflammation in hyperlipidemic patients \[[@B38], [@B40], [@B47], [@B48]\]. Such outcomes could be due to the cholesterol-lowering and/or anti-inflammatory effects of statins. These results suggest that inflammation is associated with hypercholesterolemia and lowering cholesterol by dietary control or statins may have beneficial effects on reducing LDL(-) and inflammation.

LOX-1 was implicated in vascular inflammation and the pathogenesis of atherosclerosis \[[@B49]\]. Overexpression of LOX-1 in ApoE null mice (LOX-1tg/ApoE^--/--^) increased macrophage infiltration and enhanced expressions of intracellular adhesion molecule- (ICAM-) 1 and vascular cell adhesion molecule- (VCAM-) 1 and accumulation of ox-LDL in coronary arteries \[[@B50]\]. Specific overexpression of LOX-1 in the endothelium also promoted atherosclerosis and inflammation in ApoE null mice \[[@B51]\], whereas LOX-1-knockout reduced atherosclerotic lesions and proinflammatory signals in LDL receptor- (LDLR-) null mice fed an atherogenic diet \[[@B52]\]. Those results indicate that LOX-1 plays a critical role in the pathogenesis of atherosclerosis. We recently reported that LDL(-) from STEMI patients induced production of IL-1*β*, G-CSF, and GM-CSF through a LOX-1-dependent pathway \[[@B5], [@B21]\]. Similar to human LDL(-), rabbit LDL(-) induced IL-1*β*, IL-6, and TNF-*α* through a LOX-1-dependent pathway ([Figure 4](#fig4){ref-type="fig"}). Moreover, the LOX-1 protein level was induced by rabbit LDL(-) as it was upregulated by STEMI LDL(-) (Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}). Kakutani et al. demonstrated that copper-oxidized rabbit LDL is a ligand for LOX-1 \[[@B29]\]. Those authors further demonstrated that mildly oxidized human or rabbit LDL had higher reactivity to LOX-1 than did either less- or more-oxidized LDL. Those results also supported that rabbit LDL(-) induced an inflammatory response in macrophages through a LOX-1-dependent pathway and the LDL(-)/LOX-1 axis may play important roles in inflammation and atherogenesis. However, the involvement of other receptors cannot be excluded.

Although extensively oxidized LDL was shown to be able to activate NF-*κ*B and elicit proinflammatory cytokines to various extents \[[@B53]--[@B55]\], comparing our results to results from other studies is difficult, because the source and degree of oxidation of the ox-LDL used in different studies might not be the same. In this study, we used relatively smaller amounts (20 *μ*g/ml) of LDL(-) and Cu-ox-LDL compared to larger amounts (50 to 200 *μ*g/ml) of extensively oxidized LDL used in other studies \[[@B53]--[@B56]\]. Moreover, results of this study comparing LDL(-), Cu-ox-nLDL, and Cu-ox-LDL(-) clearly showed that LDL(-) was more proinflammatory than was extensively oxidized LDL. Several different receptors, including scavenger receptors-AI and II (SR-AI and II), CD36, and LOX-1, have been identified to recognize ox-LDL and mediate ox-LDL-cellular interactions. The specificity of the different receptors to ox-LDL with the degree of oxidation is different \[[@B28]\]. SR-AI and II are considered to be the most specific for extensively oxidized LDL \[[@B57]\]; CD36 was shown to bind and internalize extensively or moderately oxidized LDL \[[@B58]\], while LOX-1 has high specificity to moderately oxidized LDL \[[@B29]\]. Activation of LOX-1 has been shown to induce several intracellular signaling pathways, including MAPKs, protein kinase C, and transcriptional factors NF-*κ*B and AP-1. Our previous study showed that STEMI LDL(-) induced higher levels of G-CSF and GM-CSF than did extensively Cu-ox-nLDL or Cu-ox-LDL(-) in macrophages \[[@B21]\]. LDL(-) is considered a moderately oxidized LDL and thus support LDL(-) being more potent in inducing the production of proinflammatory cytokines than extensively oxidized LDL.

Our results showed that LDL(-) induced activation of ERK1/2, JNK, and p38 MAPK and showed that LDL(-)-induced IL-1*β*, IL-6, and TNF-*α* can be inhibited by U0126, a MEK inhibitor, and LDL(-)-induced IL-6 and TNF-*α* can be partially inhibited by SB203580, a p38 inhibitor. Estruch et al. have demonstrated that p38 MAPK is involved in LDL(-)-induced activation of NF-*κ*B and AP-1. However, our results showed that LDL(-)-induced IL-1*β* was increased by SB203580; the mechanism underlying this is not clear and requires further investigation. In our previous report, U0126, a MEK inhibitor that inhibited activation of ERK1/2, inhibited LDL(-)-induced phosphorylation of ERK1/2. ERK signaling is known to be associated with various cellular processes, including proliferation, differentiation, and survival, and it was implicated in the pathogenesis of many diseases, including stroke, neurological diseases, and cancer \[[@B59], [@B60]\]. ERK1/2 can be regulated by mitogens and endotoxins. Upon stimulation, ERK1/2 is activated by phosphorylation of a threonine and tyrosine residue in the motif Thr-Glu-Tyr within the kinase domain \[[@B61]\]. Inhibition of the ERK signaling pathway was shown to inhibit allergic airway inflammation \[[@B62]\] and focal cerebral ischemia \[[@B63]\]. We reported that ERK1/2 is activated by LDL(-) through a LOX-1-dependent pathway and inhibition of the ERK1/2 pathway decreased the release of G-CSF and GM-CSF in STEMI LDL(-)-treated macrophages \[[@B21]\]. Moreover, ERK1/2 have been reported to be activated by ox-LDL in carotid arteries \[[@B64]\] and in human umbilical vein endothelial cells \[[@B65]\] through a LOX-1-dependent manner. In this report, we showed that in macrophages, activation of ERK1/2 is necessary for the LDL(-)-induced production of IL-1*β*, IL-6, and TNF-*α*. Moreover, ERK1/2 was shown to be activated by ox-LDL in vascular smooth muscle cells and endothelial cells via LOX-1 \[[@B66]--[@B68]\]. Inhibition of ERK suppressed cell proliferation in ox-LDL-treated vascular smooth muscle cells \[[@B66], [@B67]\] and reduced matrix metalloproteinase expression in endothelial cells \[[@B68]\]. These results suggest that the LOX-1/ERK axis may serve as a potential therapeutic target for LDL(-)-mediated atherosclerosis.

5. Conclusions {#sec5}
==============

In conclusion, our data provide evidence that an atherogenic diet induces highly proinflammatory LDL(-) in rabbits. The LDL(-) was more potent than native or extensively oxidized LDL in stimulating proinflammatory signals and cytokines. Moreover, we also elucidated that LDL(-) triggered production of IL-1*β*, IL-6, and TNF-*α* through a LOX-1/NF-*κ*B/ERK-dependent pathway. These results provide a link between an atherogenic diet and inflammation in the pathogenesis of atherosclerosis.
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Supplementary Figure 1: rabbit electronegative low-density lipoprotein (LDL(-)) induced granulocyte colony-stimulating factor (G-CSF) in THP-1 macrophages. Supplementary Figure 2: LDL(-)-induced lectin-type oxidized LDL receptor (LOX-1) expression in THP-1 cells.

###### 

Click here for additional data file.

![Characterization of LDL(-) in rabbit plasma. Rabbits were fed an atherogenic diet for 6 weeks, then LDL was isolated by ultracentrifugation and loaded onto a UnoQ6 column to separate native (n)LDL and electronegative LDL (LDL(-)). (a) Representative fast protein liquid chromatographic analysis showing the distribution of the nLDL and LDL(-). (b) Isolated nLDL and LDL(-) were analyzed by agarose gel electrophoresis.](MI2019-6163130.001){#fig1}

![Effects of nLDL and LDL(-) on production of IL-1*β*, IL-6, and TNF-*α* in THP-1 macrophages. THP-1 macrophages were incubated with 20 *μ*g/ml of nLDL or LDL(-) for 24 h, then levels of IL-1*β* (a), IL-6 (b), and TNF-*α* (c) in the medium were measured by ELISA. Values are the mean ± SD of five independent experiments. Differences between means were evaluated using Student\'s *t*-test. ^∗^*p* \< 0.05, compared to PBS- and nLDL-treated cells. Cells were incubated with 0, 10, 20, or 40 *μ*g/ml of LDL(-) for 24 h (d--f) or incubated with 20 *μ*g/ml of LDL(-) for 0, 6, 12, or 24 h (g--i). Then, levels of IL-1*β* (d, g), IL-6 (e, h), and TNF-*α* (f, i) in the medium were determined by ELISA. Values are the mean ± SE of five (in (d--f)) or four (in (g--i)) independent experiments. Data was analyzed by one-way ANOVA followed by Tukey\'s multiple comparison test. ^∗^*p* \< 0.001, compared to 0 *μ*g/ml of LDL(-) or 0 h.](MI2019-6163130.002){#fig2}

![LDL(-)-induced activation of NF-*κ*B and expressions of NF-*κ*B downstream genes. (a) THP-1 macrophages were incubated with 20 *μ*g/ml of native (n)LDL or LDL(-) for 2 h, and then protein levels of total and phosphorylated I*κ*B (I*κ*B and p-I*κ*B, respectively) and p65 (p65 and p-p65, respectively) were determined by Western blotting. *β*-Actin was used as a loading control. (b, c) Relative levels of p-I*κ*B/total I*κ*B (b) and p-p65/total p65 (c) were expressed relative to the control (PBS, relative value = 1). Values are the mean ± SD of three independent experiments. ^∗^*p* \< 0.05, compared to PBS- and nLDL-treated cells. (d) THP-1 macrophages were treated with 20 *μ*g/ml of nLDL or LDL(-) for 6 h, and levels of IL-1*β*, IL-6, TNF-*α*, CD86, and IL-10 mRNAs were determined by an RT-qPCR, normalized to levels of GAPDH mRNA, and expressed relative to levels in nLDL-treated cells (relative value = 1). ^∗^*p* \< 0.05, compared to nLDL-treated cells. (e--g) Cells were pretreated with 10 *μ*M BAY 11-7082 for 1 h and then treated with LDL(-) (20 *μ*g/ml) for 24 h. Levels of IL-1*β* (e), IL-6 (f), and TNF-*α* (g) in the medium were determined by ELISA. ^∗^*p* \< 0.05, compared to DMSO-treated cells.](MI2019-6163130.003){#fig3}

![Knockdown of lectin-type oxidized LDL receptor (LOX-1) decreased LDL(-)-induced production of IL-1*β*, IL-6, and TNF-*α*. LOX-1-, CD36-, or LacZ-knockdown (KD) cells were generated as described previously \[[@B5], [@B21]\]. Knockdown cells were incubated with PBS or 20 mg/ml LDL(-) for 24 h. Levels of IL-1*β* (a), IL-6 (b), and TNF-*α* (c) in the medium were determined. Values are the mean ± SD of three independent experiments. ^∗^*p* \< 0.05, compared to CD36- or LacZ-KD cells.](MI2019-6163130.004){#fig4}

![Effects of copper oxidation of nLDL and LDL(-) on IL-1*β*, IL-6, and TNF-*α* production in THP-1 macrophages. THP-1 macrophages were treated with 20 *μ*g/ml of nLDL, LDL(-), Cu-ox-nLDL, or Cu-ox-LDL(-) for 24 h, then levels of IL-1*β* (a), IL-6 (b), and TNF-*α* (c) in the medium were measured by ELISA. Values are the mean ± SD of three independent experiments. ^∗^*p* \< 0.05, compared to LDL(-)-treated cells.](MI2019-6163130.005){#fig5}

![Effects of LDL(-) and Cu-ox-nLDL on the activation of I*κ*B, p38, ERK1/2, and JNK in THP-1 macrophages. (a) Cells were treated with 20 *μ*g/ml of LDL(-) or Cu-ox-nLDL for 2 h, and then levels of phosphorylated I*κ*B (p-I*κ*B), total I*κ*B, p-p38, total p38, p-ERK1/2, total ERK1/2, p-JNK, and total JNK were determined by Western blotting. *β*-Actin was used as a loading control. (b--e) Protein levels were quantified using ImageJ software, and relative levels of p-I*κ*B/total I*κ*B (b), p-p38/total p38 (c), p-ERK1/2/total ERK1/2 (d), and p-JNK/total JNK (e) are expressed relative to PBS-treated cells (relative level = 1). Values are the mean ± SD of three independent experiments. ^∗^*p* \< 0.05, compared to corresponding PBS-treated and Cu-ox-nLDL-treated cells.](MI2019-6163130.006){#fig6}

![Effects of MAPK inhibitors on the LDL(-)-induced IL-1*β*, IL-6, and TNF-*α* in macrophages. Cells were preincubated with DMSO, U0126 (10 *μ*M), SB203580 (10 *μ*M), SP600125 (15 *μ*M), or LY294002 (10 *μ*M) for 1 h, then treated with LDL(-) for 24 h. Levels of IL-1*β* (a), IL-6 (b), and TNF-*α* (c) in the medium were determined by ELISA. Values are the mean ± SD of three independent experiments. ^∗^*p* \< 0.05, compared to DMSO-treated cells.](MI2019-6163130.007){#fig7}
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